Please login to the form below

Not currently logged in
Email:
Password:

Faslodex

This page shows the latest Faslodex news and features for those working in and with pharma, biotech and healthcare.

Novartis claims a rare win at ESMO for PI3K inhibitor class

Novartis claims a rare win at ESMO for PI3K inhibitor class

The results of the SOLAR-1 trial showed that giving alpelisib (BYL719) alongside AstraZeneca’s venerable product Faslodex (fulvestrant) improved progression-free survival (PFS) in patients with hormone ... months for patients receiving Faslodex alone

Latest news

More from news
Approximately 1 fully matching, plus 23 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hive

We're a healthcare communications agency that does things differently. We put patients at the heart of everything we do, while...

Latest intelligence

The new UK government-pharma industry pricing agreement – welcome news, but there are lessons to be learnt
...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again – in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics